Omnicell stock reports 7.40 percent revenue growth in Q2 2026

Omnicell stock is anchored by Q2 2026 revenue of USD 312.20 million, a 7.40 percent year-over-year increase. The medication-management company also reported diluted EPS of USD 0.52 in the quarter, while market coverage highlighted adjusted EPS of USD 0.94 versus USD 0.47 consensus.

Revenue growth meets stronger earnings

According to MarketBeat on September 15, 2026, Omnicell's latest quarter produced USD 312.20 million in revenue, up 7.40 percent year over year, and EPS of USD 0.94 compared with USD 0.47 consensus. The revenue result also exceeded the USD 310.21 million estimate cited in the same report.

The comparison matters because the earnings increase was more pronounced than the sales expansion. Finance data for the quarter show consolidated net income of USD 24.29 million and operating profit of USD 32.45 million, giving Omnicell a reported operating margin of 10.00 percent.

Guidance keeps the margin test active

Omnicell's Q3 2026 EPS guidance is USD 0.35-0.43, while full-year 2026 guidance is USD 2.15-2.30, according to MarketBeat. The range places the next-quarter midpoint at USD 0.39, below the Q2 adjusted EPS figure of USD 0.94 and makes execution through the medication-cabinet refresh cycle central to the outlook.

Omnicell describes its offering as a combination of robotics, smart devices, software and services for pharmacy care. Its investor-relations page highlights automation, labor efficiency, supply-chain control and compliance as core customer outcomes.

OMCL remains below its yearly high

OMCL was trading at USD 33.84 on Nasdaq on September 29, 2026 at 2:15 p.m. ET, with a market capitalization of USD 1.5 billion. The 52-week range was USD 29.06 to USD 55.00, placing the quote USD 21.16 below the yearly high and USD 4.78 above the low.